SCHEMBL9233000

SCHEMBL9233000

CC1(O)C=Cc2ccccc2C1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.35
CCL2 P13500 1/20 0.35
SIGMAR1 Q99720 4/20 0.35
HTR2A P28223 2/20 0.34
CHRNA7 P36544 1/20 0.34
CYP2D6 P10635 2/20 0.33
KDM4E B2RXH2 2/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CHRM2 P08172 1/20 0.32
CYP3A4 P08684 1/20 0.32
CHRM1 P11229 1/20 0.32
DRD2 P14416 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
NFKB1 P19838 1/20 0.32
CHRM3 P20309 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR2C P28335 1/20 0.32
ADRA1A P35348 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28725904 0.82 BRD4 (0.36) BRD4CCL2SIGMAR1HTR2ACHRNA7
SCHEMBL28116554 0.82 HTR2A (0.35) BRD4CCL2HTR2ACYP2D6KDM4E
SCHEMBL995535 0.79 HTR2A (0.37) BRD4CCL2HTR2ACYP2D6KDM4E
SCHEMBL6604680 0.79 BRD4 (0.35) BRD4CCL2SIGMAR1HTR2ACHRNA7
SCHEMBL15212735 0.77 RET (0.33) HTR2ACYP2D6CHRM2CHRM3RET
Methane SCHEMBL5718665 0.77 HTR2A (0.35) SIGMAR1HTR2ACYP2D6KDM4ELMNA
SCHEMBL9373705 0.74 BRD4 (0.33) BRD4CCL2SIGMAR1HTR2ACYP2D6
SCHEMBL4784825 0.74 CYP2D6 (0.35) BRD4CCL2HTR2ACYP2D6KDM4E
SCHEMBL27734830 0.73 HTR2A (0.34) HTR2ACYP2D6ATM
SCHEMBL27942046 0.72 ALDH1A1 (0.36) BRD4CCL2SIGMAR1HTR2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3265447-B1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION HUNTSMAN ADVANCED MAT AMERICAS LLC (US) 2023-03-01 EP disclosed
CN-107428709-B Cationic direct dyes 巴斯夫欧洲公司 2021-10-08 CN disclosed
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition HUNTSMAN ADVANCED MATERIALS AMERICAS LLC 2018-02-01 US disclosed
EP-3265447-A1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION Huntsman Advanced Materials Americas LLC (US) 2018-01-10 EP disclosed
EP-0661322-A2 Modified polyepoxy compound, process for producing the compound, and epoxy resin composition SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1995-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition CRYZ, PIEZO1, PSMD12 BRD4 813/4885CCL2 4778/4885SIGMAR1 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.